Fennec Pharmaceuticals Hits Day Low of CAD 8.26 Amid Price Pressure

Fennec Pharmaceuticals, Inc. experienced significant volatility today, with the stock hitting an intraday low of CAD 8.26, reflecting a notable decline of 18.62%. This drop is part of a broader trend, as the company has seen a 22.91% decrease over the past week and a 32.18% decline in the last month. In comparison, the S&P/TSX 60 index has shown a modest gain of 0.08% today and a decline of only 2.69% over the past week. Over the past year, Fennec Pharmaceuticals has underperformed the index, with a loss of 12.68% compared to the S&P/TSX 60's gain of 22.62%. The company's financial metrics indicate challenges, including a negative book value and a weak long-term growth outlook, with operating profit growth at just 5.44% over the last five years. Additionally, the company's ability to service its debt appears limited, as evidenced by a poor EBIT to interest ratio of -11.26. Overall, Fennec Pharmaceuticals continues to navigate a challenging market environment, reflected in its recent stock performance.